NEUROCRINE BIOSCIENCES INC Quarterly Costs and Expenses in USD from Q2 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Neurocrine Biosciences Inc quarterly/annual Costs and Expenses history and growth rate from Q2 2019 to Q4 2024.
  • Neurocrine Biosciences Inc Costs and Expenses for the quarter ending December 31, 2024 was $486M, a 33.1% increase year-over-year.
  • Neurocrine Biosciences Inc Costs and Expenses for the twelve months ending December 31, 2024 was $1.78B, a 9.08% increase year-over-year.
  • Neurocrine Biosciences Inc annual Costs and Expenses for 2024 was $1.78B, a 9.08% increase from 2023.
  • Neurocrine Biosciences Inc annual Costs and Expenses for 2023 was $1.64B, a 32% increase from 2022.
  • Neurocrine Biosciences Inc annual Costs and Expenses for 2022 was $1.24B, a 20.2% increase from 2021.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $1.78B $486M +$121M +33.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-10
Q3 2024 $1.66B $438M +$80.7M +22.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $1.58B $445M +$65.7M +17.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $1.52B $416M -$119M -22.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $1.64B $365M +$56.3M +18.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-10
Q3 2023 $1.58B $358M +$57.5M +19.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $1.52B $379M +$55.6M +17.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $1.47B $535M +$227M +73.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $1.24B $309M -$39.7M -11.4% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-10
Q3 2022 $1.28B $300M +$48.6M +19.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-31
Q2 2022 $1.23B $324M +$97.4M +43.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 $1.13B $308M +$102M +49.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $1.03B $348M +$172M +97.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-09
Q3 2021 $859M $252M -$51.3M -16.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $910M $226M +$300K +0.13% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $910M $205M +$26.9M +15.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $883M $176M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-09
Q3 2020 $303M +$171M +129% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-01
Q2 2020 $226M +$76.7M +51.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $178M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q3 2019 $132M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $149M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.